sanofi aventis sa drug pipeline maturing alzheimers drug fails sanofi aventis sa said its pipeline of late stage experimental drugs was maturing but a drug for alzheimers disease which analysts had viewed as high risk failed in clinical studies sanofi said it could make submissions for approval with regulators by the end of and had projects in advanced clinical trials "we have products which might be potential blockbusters " with sales of more than billion euros &# billion a year said research head marc cluzel highlighting the potential of medicines for depression diabetes thrombosis and cancer pressure on the french company has increased since june when its antiobesity drug acomplia known as zimulti in the u s was rejected by a u s expert panel the alzheimers drug xaliproden failed to show a significant effect against the disease in trials but is being investigated in reducing pain linked to chemotherapy 
